subscribeSubscribe
Risks of Picato for actinic keratosis outweigh benefits

Risks of Picato for actinic keratosis outweigh benefits
EMA
30 Apr 2020
Share Share
EMA confirms skin cancer risk with LEO`s Picato

EMA confirms skin cancer risk with LEO`s Picato
Selina McKee PHARMATIMES
20 Apr 2020
Share Share
EMA Begins Publishing All Health Professional Communications

EMA Begins Publishing All Health Professional Communications
Michael Mezher RAPS
14 Feb 2020
Share Share
Ingenol mebutate gel: suspension of the licence due to risk of skin malignancy

Ingenol mebutate gel: suspension of the licence due to risk of skin malignancy
GOVUK
13 Feb 2020
Share Share
LEO issues Picato recall

LEO issues Picato recall
Anna Smith PHARMA TIMES
01 Feb 2020
Share Share
EMA suspends Picato as a precaution while review of skin cancer risk continue

EMA suspends Picato as a precaution while review of skin cancer risk continue
EMA
18 Jan 2020
Share Share
Ingenol mebutate gel (Picato?): increased incidence of skin tumours seen

Ingenol mebutate gel (Picato?): increased incidence of skin tumours seen
MHRA
18 Oct 2019
Share Share
EMA Begins Review of Skin Cancer Data for Patients Using Picato

EMA Begins Review of Skin Cancer Data for Patients Using Picato
Zachary Brennan RAPS
06 Sep 2019
Share Share
Perrigo UK Finco`s Generic Ingenol Mebutate Receives Approval in US

Perrigo UK Finco`s Generic Ingenol Mebutate Receives Approval in US
FDA
08 Jan 2019
Share Share
Perrigo Uk Finco`s Generic Ingenol MebutateReceives Tentative Approval in US

Perrigo Uk Finco`s Generic Ingenol MebutateReceives Tentative Approval in US
FDA
09 Oct 2018
Share Share